As part of the realignment, Harvard Bioscience will reduce its global workforce by approximately 13 percent by eliminating certain operational redundancies across several sites, creating a leaner, more nimble organization. It plans to reinvest some of the savings into its China expansion, sales and marketing and product development initiatives, in order to drive growth.
AAIPharma Services, Corp. and Cambridge Major Laboratories, Inc. have announced the appointment...
Forest Laboratories says it plans to cut about 500 jobs as part of a plan to trim $500 million...
Timothy C. Tyson, Chairman of Aptuit LLC, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO), completing the company's senior management leadership team. Dr. Goldman will focus his efforts on the growth of Aptuit as a leading provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions.
Simulations Plus, Inc., today announced that Ms. Momoko Beran has notified the board of directors of her plan to retire effective as of January 15, 2014.
Actavis has cut about 350 U.S. sales jobs since its purchase of Warner Chilcott closed in October. Actavis said it has restructured its U.S. specialty brands unit. There are now about 750 sales representatives and managers in the division.
Pfizer Inc. says it will close one of its three manufacturing plants in Puerto Rico by 2017. The world's largest drug maker says the manufacturing of products at its plant in the north coastal city of Barceloneta will be moved elsewhere.
Xcelience announced today the hiring of Joseph Iacobucci as Vice President of Clinical Supplies and Services. Mr. Iacobucci brings nearly 30 years of experience in clinical packaging and supply services, including 23 years as a Vice President for Clinical Systems, Inc.
Merck announced Friday that it would cease active ingredient production at one of its plants in Puerto Rico in a blow to a city once considered a pharmaceutical hub. The company said production at a plant in the north coastal city of Barceloneta will end by late 2014 as part of a global restructuring.
Bristol-Myers Squibb Company has announced a series of related changes within its Senior Management Team. To support its ongoing success as a BioPharma leader, the company is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization.
Actavis is closing its North Carolina plant putting about 310 people out of work. Actavis will take until the middle of 2015 to close the plant in Lincoln County, which makes creams and ointments.
Prostate cancer therapy maker Dendreon said that sales fell in the third quarter, and announced plan to eliminate about 150 jobs and cut $125 million in annual spending. The cost cuts come in the wake of disappointing sales of Dendreon Corp.'s Provenge therapy.
IPS-Integrated Project Services, Inc. (IPS) today announced the appointment of Peter Hanson as Director of Process Architecture in Asia and Europe, the Middle East and Africa (EMEA) Regions.
CVS Caremark today announced the appointment of William Shrank, MD to the position of Chief Scientific Officer and Chief Medical Officer, Provider Innovation and Analytics. Dr. Shrank will oversee the company's overall research and clinical program development with the goal of delivering new methods of evaluating innovative programs and initiatives.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced the appointment of Paul Marshall as senior vice president of technical operations and Brian Drazba as vice president of finance and chief financial officer. Mr. Marshall will be responsible for A.P. Pharma’s manufacturing operations, including for APF530, the company’s lead product candidate.
Packaging Coordinators Inc. (PCI) has announced the addition of Jaime Houghton to its North American Clinical Services team. Houghton will be based out of PCI’s state-of-the-art North American Clinical packaging and distribution site located in Rockford, IL.
Teva Pharmaceuticals Ltd. announced Wednesday its CEO had resigned, following a public uproar over a contentious restructuring plan set to cut thousands of jobs worldwide. In a statement, Teva said its board of directors and President and CEO Jeremy Levin had agreed for him to step down. It gave no reason for the resignation, but the shakeup exposed cracks in the leadership of the world's largest generic drug maker.
Vertex Pharmaceuticals said that it is cutting 15 percent of its workforce as a competitor's treatment for hepatitis C edges closer to approval. It also reported a loss for its fiscal third quarter, including lower-than-expected revenue.
Eli Lilly and Company has announced that Alfonso "Chito" Zulueta will be promoted to senior vice president and president of the Emerging Markets business effective Jan. 1, 2014. Zulueta will replace Jacques Tapiero who will retire Jan. 31, 2014, after 31 years of service to the company.
Mallinckrodt has announced three appointments to the company’s senior management team. This will round out Mallinckrodt’s executive leadership and help drive the company’s strategic focus toward growing its core business as a specialty pharmaceutical company.
Specialty drugmaker Amarin Corp. is eliminating half of its employees in the wake of an overwhelmingly negative Food and Drug Administration meeting that has put the future of the company's lead product in jeopardy. The company did not say how many employees would be affected. At the end of 2012...
Eli Lilly said Tuesday that Jackson Tai, a former investment banker and CEO of DBS Bank, will join its board Nov. 1. Eli Lilly and Co. said Tai, 63, worked as an investment banker for JPMorgan Chase & Co. for 25 years and was later CEO of DBS Group Holdings Ltd. and DBS Bank Ltd. of...
Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announces today the promotion of Mark Weinberg, M.D., MBA to Vice President of Global Clinical Science and the appointment of Robin J. McGarry, M.D. to the position of Vice President, Global Medical Safety Head.
As the world's leading maker of generic drugs, Teva Pharmaceutical Industries Ltd. is a huge source of pride for Israel. Now, following an announcement of planned layoffs and revelations it enjoys sweeping tax exemptions, it is on the defensive and fighting to save its reputation as the country's...
Eisai has announced that it will increase the number of sales representatives for the anti-obesity agent BELVIQ® (lorcaserin hydrochloride) by more than 200 contract employees to increase awareness and education about BELVIQ among healthcare providers.
AMRI today announced the appointment of Michael A. Luther, Ph.D., as Senior Vice President, Discovery, effective October 28, 2013. Dr. Luther will report to Thomas E. D'Ambra, Ph.D., President and CEO.Dr. Luther will lead AMRI's global discovery organization, which provides biology and chemistry services to the biopharmaceutical industry, with locations in the U.S., Singapore and Hyderabad, India.
ISPE has announced the results of its 2013-2014 International Board of Directors election, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors. The Board will be responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2013 ISPE Annual Meeting.
Teva Pharmaceuticals says it will cut 5,000 employees by the end of next year as part of a restructuring designed to slim the drugmaker's business and make it more efficient. The Israeli company says the cuts amount to a 10 percent global workforce reduction.
- Page 1